Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04399252 · ClinicalTrials.gov registry record · NA
Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 182
- Enrollment target
NCT04399252 is a NA study that has completed, run by Duke University. The registered enrollment target is 182 participants.
The verdict
NCT04399252, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 182 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of the probiotic Lactobacillus rhamnosus GG (LGG) and the effect of COVID-19 on the microbiome (the microorganisms that live in and on the human body) in exposed household contacts of COVID-19. This is a randomized, double-blind, placebo-controlled study, meaning subjects will be randomly assigned to receive LGG or a placebo (an inactive substance given in the same form as the active substance) and will not know which product they are receiving. Subjects will participate in the study for around 60 days. All subjects must refrain from taking any other probiotics while on study. All subjects must have access to e-mail and the internet to complete study questionnaires. Participation in this study entails taking LGG/placebo for 28 days, responding to questionnaires, and providing stool and nasal swab samples.
Interventions
- DIETARY_SUPPLEMENT Lactobacillus rhamnosus GG
- DIETARY_SUPPLEMENT Lactobacillus rhamnosus GG Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 182 participants |
| Start Date | 2020-06-24 |
| Est. Completion | 2021-07-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04399252
The ClinicalTrials.gov registry entry for NCT04399252 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 182 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Lactobacillus rhamnosus GG is the first listed.
NCT04399252 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04399252 about?
NCT04399252 is a clinical study titled "Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19". The purpose of this study is to evaluate the effect of the probiotic Lactobacillus rhamnosus GG (LGG) and the effect of COVID-19 on the microbiome (the microorganisms that live in and on the human body) in exposed household contacts of COVID-19. This is a randomized, double-blind, placebo-controlled...
What is the current status of trial NCT04399252?
This trial is currently completed. It is a NA study. The enrollment target is 182 participants. The study started on 2020-06-24. Estimated completion is 2021-07-08.
What interventions are being tested in trial NCT04399252?
The interventions under investigation include: Lactobacillus rhamnosus GG (DIETARY_SUPPLEMENT), Lactobacillus rhamnosus GG Placebo (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT04399252?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.